Jennifer R. Grandis
Affiliations: | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
Pathology, Cell Biology, Molecular BiologyGoogle:
"Jennifer Grandis"Children
Sign in to add trainee| Amanda L. Boehm | grad student | 2007 | University of Pittsburgh |
| Rebecca J. Leeman-Neill | grad student | 2008 | University of Pittsburgh |
| Neil Bhola | grad student | 2009 | University of Pittsburgh |
| Kelly M. Quesnelle | grad student | 2012 | University of Pittsburgh |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lee RH, Johnson DE, Grandis JR. (2023) To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer. Cancer Research. 83: 3162-3164 |
| Jagadeeshan S, Prasad M, Badarni M, et al. (2023) Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer. Cancer Research |
| Long Z, Grandis JR, Johnson DE. (2022) Emerging tyrosine kinase inhibitors for head and neck cancer. Expert Opinion On Emerging Drugs. 1-12 |
| Brand TM, Hartmann S, Bhola NE, et al. (2022) Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research. 82: 3187 |
| Brand TM, Hartmann S, Bhola NE, et al. (2022) Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research. 82: 3188 |
| Qureshy Z, Li H, Zeng Y, et al. (2022) STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Li H, Peyser ND, Zeng Y, et al. (2022) NSAIDs Overcome Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models. Cancers. 14 |
| Swaney DL, Ramms DJ, Wang Z, et al. (2021) A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science (New York, N.Y.). 374: eabf2911 |
| Bouhaddou M, Lee RH, Li H, et al. (2021) Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. Jci Insight |
| Bhola NE, Njatcha C, Hu L, et al. (2021) PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. Head & Neck |